Cancer Family
Malignant Thoracic Neoplasm
CI-CAN-00000256Explore in graph →
2,775 active trials51 approved drugs626 evidence items
- NCIt
- C3576
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000256Explore in graph →
Clinical trials
11,499 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,528)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03625323 | Combination Study With Soluble LAG-3 Fusion Protein Eftilagimod Alpha (IMP321) and Pembrolizumab in Patients With Previously Untreated Unresectable or Metastatic NSCLC, or Recurrent PD-X Refractory NSCLC or With Recurrent or Metastatic HNSCC(TACTI-002) | completed | Phase 2 | 187 | Immutep S.A.S.INDUSTRY | 1 | Apr 22, 2026 | clinicaltrials |
| NCT03710876 | Efficacy & Safety of rAd-IFN Administered With Celecoxib & Gemcitabine in Patients With Malignant Pleural Mesothelioma(INFINITE) | completed | Phase 3 | 53 | Ferring Ventures Limited |
| 9 |
| Apr 21, 2026 |
| clinicaltrials |
| NCT06380361 | InvestigatioN of a Smart Probe for Lung lEsion Characterization Using Impedance Technology(INSPECT) | completed | N/A | 30 | SensomeINDUSTRY | 2 | Apr 21, 2026 | clinicaltrials |
| NCT01802632 | AZD9291 First Time In Patients Ascending Dose Study(AURA) | completed | Phase 1 / Phase 2 | 603 | AstraZenecaINDUSTRY | 10 | Apr 20, 2026 | clinicaltrials |
| NCT05519865 | A Study of Tucidinostat Combined With Tislelizumab as First-line Treatment in Advanced NSCLC | completed | Phase 2 | 118 | Chipscreen Biosciences, Ltd.INDUSTRY | 1 | Apr 20, 2026 | clinicaltrials |
| NCT07532447 | Metabolomic Characteristics of Patients With Non-small Cell Lung Cancer in Plasma, Tissue and Exhaled Breath Condensate | completed | — | 74 | People's Hospital of Xinjiang Uygur Autonomous RegionOTHER | 1 | Apr 20, 2026 | clinicaltrials |
| NCT03881488 | Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies | completed | Phase 1 | 100 | Compass TherapeuticsINDUSTRY | 1 | Apr 17, 2026 | clinicaltrials |
| NCT06286592 | LUNGevity: Lung Cancer Stigma Community Based Participatory Research | completed | N/A | 108 | Rutgers, The State University of New JerseyOTHER | 1 | Apr 17, 2026 | clinicaltrials |
| NCT02816697 | Implementation of a System-level Tobacco Treatment Intervention | completed | N/A | 263 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 16, 2026 | clinicaltrials |
| NCT03634241 | Pembrolizumab in Preventing Lung Cancer in Patients With Stage I-II Non-Small Cell Lung Cancer or High-Risk Pulmonary Nodules, the IMPRINT-Lung Study | completed | Phase 2 | 45 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 16, 2026 | clinicaltrials |
| NCT04479306 | Osimertinib in Combination With Alisertib or Sapanisertib for the Treatment of Osimertinib-Resistant EGFR Mutant Stage IIIB or IV Non-Small Cell Lung Cancer | completed | Phase 1 | 37 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 16, 2026 | clinicaltrials |
| NCT07532057 | The Effect of Pulmonary Rehabilitation on Pulmonary Function Tests, Exercise Capacity, and Quality of Life in Patients With Advanced-Stage Lung Cancer Receiving Chemotherapy(PR-LUNGCA-2019) | completed | N/A | 30 | Istanbul Medipol University HospitalOTHER | 1 | Apr 16, 2026 | clinicaltrials |
| NCT01630733 | A Multinational, Randomized, Open-Label Study of Custirsen In Patients With Advanced or Metastatic (Stage IV) Non-Small Cell Lung Cancer(ENSPIRIT) | completed | Phase 3 | 664 | Achieve Life SciencesINDUSTRY | 14 | Apr 15, 2026 | clinicaltrials |
| NCT01118676 | Cilengitide Together With Radiochemotherapy in Patients With Locally Advanced Non Small Cell Lung Cancer | completed | Phase 1 | 14 | Institut Claudius RegaudOTHER | 1 | Apr 14, 2026 | clinicaltrials |
| NCT03446547 | Ablative STEreotactic RadiOtherapy wIth Durvalumab (MEDI4736)(ASTEROID) | completed | Phase 2 | 106 | Vastra Gotaland RegionOTHER_GOV | 3 | Apr 14, 2026 | clinicaltrials |
| NCT05826366 | Imfinzi/Imjudo NSCLC Japan PMS_Japan Post-Marketing Surveillance (PMS) Study - CEI/SCEI | completed | — | 296 | AstraZenecaINDUSTRY | 1 | Apr 14, 2026 | clinicaltrials |
| NCT07073898 | UG3 Pilot Clinical Trial | completed | N/A | 65 | University of UtahOTHER | 1 | Apr 14, 2026 | clinicaltrials |
| NCT07526961 | Real-World Outcomes of First-Line Nivolumab + Ipilimumab With Chemotherapy in Non-Small Cell Lung Cancer in Poland | completed | — | 240 | Bristol-Myers SquibbINDUSTRY | 1 | Apr 14, 2026 | clinicaltrials |
| NCT02259218 | Metabolomic and Epigenetic Profiling of Bodyfluids From Lung and Brain Cancer Receiving Radiation Therapy | completed | — | 273 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT02649569 | Continuous Activity Monitoring During Fractionated Radiotherapy in Patients With Head and Neck, Lung, or Gastrointestinal Cancer | completed | — | 41 | Montefiore Medical CenterOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT03102229 | Real-time Activity Monitoring to Prevent Admissions During RadioTherapy(RAMPART) | completed | N/A | 40 | Montefiore Medical CenterOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT03115398 | A Simple Walking Program to Enhance Concurrent Chemoradiotherapy Delivery | completed | N/A | 166 | Montefiore Medical CenterOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT05106374 | Risk of Chemotherapy Toxicity in Older Patients With Blood Cancer or Non-small Cell Lung Cancer | completed | — | 182 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT05461430 | Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)(TraveraRTGx) | completed | — | 72 | Travera IncINDUSTRY | 1 | Apr 13, 2026 | clinicaltrials |
| NCT06191939 | Adapting and Testing a Novel Self-Compassion Intervention to Reduce Lung Cancer Stigma(MSC-LC) | completed | N/A | 79 | Loyola Marymount UniversityOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT03236935 | Phase Ib of L-NMMA and Pembrolizumab | completed | Phase 1 | 12 | The Methodist Hospital Research InstituteOTHER | 1 | Apr 9, 2026 | clinicaltrials |
| NCT03523702 | The Selective Personalized Radio-Immunotherapy for Locally Advanced NSCLC Trial(SPRINT) | completed | Phase 2 | 25 | Montefiore Medical CenterOTHER | 1 | Apr 9, 2026 | clinicaltrials |
| NCT04081779 | Survivorship Care Plans and Telehealth Education for the Improvement of Access to Cancer Survivorship, the IMPACT Study | completed | N/A | 261 | Fred Hutchinson Cancer CenterOTHER | 1 | Apr 8, 2026 | clinicaltrials |
| NCT04488354 | Long-term Follow-up Study for Patients Treated With CLBR001 CAR-T | completed | Phase 1 | 16 | Calibr, a division of Scripps ResearchOTHER | 1 | Apr 8, 2026 | clinicaltrials |
| NCT04660097 | Anlotinib Plus Durvalumab-Platinum-Etoposide in First-line Treatment Extensive Small-cell Lung Cancer | completed | Phase 2 | 34 | Henan Cancer HospitalOTHER_GOV | 1 | Apr 8, 2026 | clinicaltrials |
| NCT06973161 | ESPERANZA: External Control Arm Study for T-DXd for Patients With HER2 IHC3+ Solid Tumors | completed | — | 140 | AstraZenecaINDUSTRY | 12 | Apr 8, 2026 | clinicaltrials |
| NCT05110196 | Study of Capmatinib in Indian Patients With MET Exon 14 Skipping Mutation Positive Advanced NSCLC. | completed | Phase 4 | 50 | Novartis PharmaceuticalsINDUSTRY | 1 | Apr 7, 2026 | clinicaltrials |
| NCT07143513 | Real World Evaluation of Sotorasib Among Chinese Non-Small Cell Lung Cancer Patients | completed | — | 102 | AmgenINDUSTRY | 1 | Apr 7, 2026 | clinicaltrials |
| NCT02087423 | A Global Study to Assess the Effects of MEDI4736 (Durvalumab) in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer(ATLANTIC) | completed | Phase 2 | 446 | AstraZenecaINDUSTRY | 18 | Apr 6, 2026 | clinicaltrials |
| NCT03158129 | Nivolumab With or Without Ipilimumab or Chemotherapy in Treating Patients With Previously Untreated Stage I-IIIA Non-small Cell Lung Cancer | completed | Phase 2 | 101 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 6, 2026 | clinicaltrials |
| NCT05362318 | Project HEALS (Helping and Empowering pAtients for Living a Life Smoke-free | completed | N/A | 21 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Apr 6, 2026 | clinicaltrials |
| NCT05387512 | Real-world Association Between Concomitant Beta-blocker Exposure and Anti-PD-1/PD-L1 Treatment Outcomes in Advanced Non-Small Cell Lung Cancer | completed | — | 60 | Affiliated Hospital of Nantong UniversityOTHER | 1 | Apr 6, 2026 | clinicaltrials |
| NCT04256421 | A Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Patients With Untreated Extensive-Stage Small Cell Lung Cancer(SKYSCRAPER-02) | completed | Phase 3 | 490 | Hoffmann-La RocheINDUSTRY | 23 | Apr 3, 2026 | clinicaltrials |
| NCT03589547 | Durvalumab and Consolidation SBRT Following Chemoradiation for Locally Advanced Stage III Non-Small Cell Lung(358) | completed | Phase 2 | 11 | Brown UniversityOTHER | 1 | Apr 2, 2026 | clinicaltrials |
| NCT05873439 | Genomically Guided Radiation Dose Personalization in Locally Advanced NSCLC | completed | Early Phase 1 | 3 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Apr 1, 2026 | clinicaltrials |
| NCT04677595 | Study of Capmatinib in Chinese Adult Patients With Advanced Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation(GeoMETry-C) | completed | Phase 2 | 36 | Novartis PharmaceuticalsINDUSTRY | 1 | Mar 31, 2026 | clinicaltrials |
| NCT06225414 | Empowering Hispanic Patients' Lung Cancer Screening Uptake (Empower Latinx) | completed | N/A | 60 | University of California, IrvineOTHER | 1 | Mar 30, 2026 | clinicaltrials |
| NCT07489339 | MDT-Based Nursing for Small Cell Lung Cancer During Chemo-Immunotherapy(SCLC-MDT) | completed | N/A | 200 | Shanxi Province Cancer HospitalOTHER | 1 | Mar 30, 2026 | clinicaltrials |
| NCT03678350 | Light Dosimetry for Photodynamic Therapy With Porfimer Sodium in Treating Participants With Malignant Mesothelioma or Non-Small Cell Lung Cancer With Pleural Disease Undergoing Surgery | completed | Phase 1 | 9 | Roswell Park Cancer InstituteOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT04351256 | Thoracic Radiotherapy Plus Durvalumab in Elderly and/or Frail NSCLC Stage III Patients Unfit for Chemotherapy(TRADE-hypo) | completed | Phase 2 | 51 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT06132607 | 3D Lung Reconstructions Using Open-source Software for Lung Cancer Surgery(3D-LUNG) | completed | — | 13 | Erik de LoosOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT06338592 | The MyLungHealth Study Protocol: Engaging Patients to Enable Interoperable Lung Cancer Decision Support at Scale(MyLungHealth) | completed | N/A | 31,303 | University of UtahOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT07498972 | Evidence-Based Nursing Plus Progressive Exercise for Cancer-Related Fatigue in Advanced Lung Cancer(ENPE-CRF) | completed | N/A | 100 | Shanxi Province Cancer HospitalOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT03915951 | An Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600-mutant Non-small Cell Lung Cancer | completed | Phase 2 | 98 | PfizerINDUSTRY | 5 | Mar 24, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Apr 22, 2026source: clinicaltrials